How can you maintain weight loss after stopping a GLP-1
For maximum results: Yes For budget-conscious: Semaglutide still excellent For significant obesity: Tirzepatide preferred For moderate weight loss: Either works well Ongoing Research: SURMOUNT-MMO Trial: Studying tirzepatide in patients with obesity and multiple comorbidities Evaluating cardiovascular outcomes Results pending (expected 2025-2026) Future Developments: Oral tirzepatide formulations in research Monthly injection versions being studied Combinations with other therapies Understanding affordable Mounjaro alternatives helps you access tirzepatide at prices that fit your budget
UPR-driven tumor dormancy and therapeutic resistance Beyond its role in active tumor growth, the UPR plays a pivotal role in cancer cell dormancy, long-term survival, and resistance to anticancer therapies
Cardiovascular effects: Phase 2 trial data indicate that retatrutide was associated with modest increases in resting heart rate, consistent with observations seen with other GLP-1 receptor agonists
I., Gallavan, R
This reparative effect is mediated, at least in part, through the upregulation and reorganization of key regulatory proteins, most notably protein kinase C (PKC) and the tight junction scaffolding protein zonula occludens-2 (ZO-2), thereby facilitating the reassembly and functional recovery of the tight junction complex (161)